SIR-Spheresin 2nd-line Treatment of mCRC
Lim30SIR-Spheres†(+ 5FU/LV)70%33% 5.3 mo
van Hazel 25SIR-Spheres†+ irinotecan 48%6.0 mo§12.2 mo
9.2 mo§L
Limet al. BMC Cancer 2005;5:132. van Hazel et al. J Clin Oncol2009;27:4089–95. Schoemaker et al. Brit J Cancer 2004;91:1434–41.
Van Cutsem et al. Brit J Cancer 2005;92:1055–62. Seymour et al. Lancet2007;370:143–52. Fuchs et al. JCO 2007;21:807–14.
Sobrero et al. J Clin Oncol2008;26:2311–9. de Cerqueira Mathias et al. ECCO2007;5: Abs P3055. Wilke et al. ECCO2007;5: Abs P3025.
Cunningham et al. N Engl J Med 2004;351:337–45. Hecht et al. Cancer 2007;110:980–8.Van Cutsem et al. J Clin Oncol2007;25:1658–64.
Van Cutsem et al. Ann Oncol2008;19:92–8. Muro et al. Jpn J Clin Oncol 2009;39:321–6.
|